Details of the Drug

General Information of Drug (ID: DMG281S)

Drug Name

Carboplatin

Synonyms

Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

371.25

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 27.18 +/- 11.28 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 9.06 +/- 0.74 mg/L [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance: The total body clearance of drug is 4.4 L/h [3]
Elimination: Carboplatin is 65% eliminated in the urine within 12 hours, and 71% eliminated within 24 hours [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.1 - 2 hours [3]
Metabolism: The drug is not metabolised [6]
Unbound Fraction: The unbound fraction of drug in plasma is 1% [7]
Vd: The volume of distribution (Vd) of drug is 16 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 14 mg/mL [4]

Chemical Identifiers

Formula: C6H12N2O4Pt
IUPAC Name: azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
Canonical SMILES: C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
InChI: InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2
InChIKey: VSRXQHXAPYXROS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 426756
ChEBI ID: CHEBI:31355
CAS Number: 41575-94-4
DrugBank ID: DB00958
TTD ID: D0X7HM
VARIDT ID: DR00469
INTEDE ID: DR0272
ACDINA ID: D00913

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
High affinity copper uptake protein 1 (SLC31A1)	DTP8L4F	COPT1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Quinone reductase 1 (NQO1)	DENP5RY	NQO1_HUMAN	Substrate	[10]
Glutathione S-transferase pi (GSTP1)	DEK6079	GSTP1_HUMAN	Substrate	[10]
Metallothionein-1A (MT1A)	DE5ME8A	MT1A_HUMAN	Substrate	[10]
Myeloperoxidase (MPO)	DEA3U9Y	PERM_HUMAN	Substrate	[10]
Metallothionein-2A (MT2A)	DEFKGT7	MT2_HUMAN	Substrate	[10]
Glutathione S-transferase mu-1 (GSTM1)	DEYZEJA	GSTM1_HUMAN	Substrate	[10]
Glutathione S-transferase theta-1 (GSTT1)	DE3PKUG	GSTT1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Carboplatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Carboplatin caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[37]
Framycetin	DMF8DNE	Moderate	Increased risk of nephrotoxicity by the combination of Carboplatin and Framycetin.	Alcoholic liver disease [DB94]	[38]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Carboplatin and Inotersen.	Amyloidosis [5D00]	[39]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Roflumilast.	Asthma [CA23]	[39]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Carboplatin and Kanamycin.	Bacterial infection [1A00-1C4Z]	[38]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Carboplatin and Streptomycin.	Bacterial infection [1A00-1C4Z]	[38]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
ABT-492	DMJFD2I	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[40]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Carboplatin and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[41]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Anisindione	DM2C48U	Moderate	Increased plasma concentration of Carboplatin and Anisindione due to competitive binding of plasma proteins.	Coagulation defect [3B10]	[42]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Carboplatin and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[41]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Carboplatin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[43]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Carboplatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[44]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Carboplatin and Denosumab.	Low bone mass disorder [FB83]	[45]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Carboplatin and Thalidomide.	Multiple myeloma [2A83]	[46]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Tecfidera.	Multiple sclerosis [8A40]	[47]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Carboplatin and Siponimod.	Multiple sclerosis [8A40]	[37]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Carboplatin and Fingolimod.	Multiple sclerosis [8A40]	[48]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Ocrelizumab.	Multiple sclerosis [8A40]	[49]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Carboplatin and Ozanimod.	Multiple sclerosis [8A40]	[39]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[50]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Carboplatin due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[40]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Canakinumab.	Rheumatoid arthritis [FA20]	[51]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Carboplatin and Rilonacept.	Rheumatoid arthritis [FA20]	[51]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Carboplatin and Golimumab.	Rheumatoid arthritis [FA20]	[52]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Carboplatin and Leflunomide.	Rheumatoid arthritis [FA20]	[44]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Carboplatin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[53]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Carboplatin and Azathioprine.	Transplant rejection [NE84]	[37]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Carboplatin and Ganciclovir.	Virus infection [1A24-1D9Z]	[37]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Carboplatin and Valganciclovir.	Virus infection [1A24-1D9Z]	[37]
-----------


⏷ Show the Full List of 35 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Water	E00035	962	Solvent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Carboplatin 50mg/5ml injectable	50mg/5ml	Injectable	Injection
Carboplatin 50mg/5ml injectable	50mg/5ml	Injectable	Intravenous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076039.
3	Dailymed: Carboplatin Intravenous Injection
4	BDDCS applied to over 900 drugs
5	Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD: Clinical pharmacokinetics of carboplatin. J Clin Pharmacol. 1988 Mar;28(3):208-15. doi: 10.1002/j.1552-4604.1988.tb03134.x.
6	Shin JM, Kim N: Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013 Jan;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25. Epub 2013 Jan 8.
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
9	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
10	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
11	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
12	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
13	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
14	The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
15	Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
16	Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
19	Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
20	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
21	Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
22	Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
23	Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
24	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
25	Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
26	Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
27	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
28	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
29	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
30	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
31	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
32	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
33	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
34	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
35	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
36	Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
37	Cerner Multum, Inc. "Australian Product Information.".
38	Product Information. Paraplatin (carboplatin). Bristol-Myers Squibb, Princeton, NJ.
39	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
40	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
41	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
42	Le AT, Hasson NK, Lum BL "Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy." Ann Pharmacother 31 (1997): 1006-8. [PMID: 9296241]
43	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
44	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
45	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
46	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
47	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
48	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
50	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
51	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
52	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
53	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]